Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mavacamten PK in Healthy Chinese Subjects
NCT05135871Phase 1Completed
- Sponsor
- LianBio
- Start
- Oct 2021
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of mavacamten in hypertrophic cardiomyopathy (HCM) (4 cohorts), sponsored by LianBio. Primary endpoints: Area Under the Curve (0-last), AUC(0-inf) at Day 75, Maximum Concentration at Day 75 and 4 more. Started Oct 2021; status: completed.
02
Drugs
mavacamten
03
Conditions
hypertrophic cardiomyopathy (HCM)
Beyond the preview
Go deeper on NCT05135871.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05135871.